Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Clicks: 508
ID: 269069
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #22 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.).
Reference Key
a2012thecontinuous Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Palumbo A;Hajek R;Delforge M;Kropff M;Petrucci MT;Catalano J;Gisslinger H;Wiktor-Jędrzejczak W;Zodelava M;Weisel K;Cascavilla N;Iosava G;Cavo M;Kloczko J;Bladé J;Beksac M;Spicka I;Plesner T;Radke J;Langer C;Ben Yehuda D;Corso A;Herbein L;Yu Z;Mei J;Jacques C;Dimopoulos MA; ;;
Journal The New England journal of medicine
Year 2012
DOI
DOI not found
URL
https://www.pubmed.gov/22571200/
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged Comparative Study 80 and over Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study follow-up studies neutropenia / chemically induced induction chemotherapy antineoplastic combined chemotherapy protocols / adverse effects disease-free survival prednisone / adverse effects oral neoplasms kaplan-meier estimate maintenance chemotherapy antineoplastic combined chemotherapy protocols / therapeutic use* prednisone / administration & dosage* initials='g' affs=[] is_editor=false suffix=none equal_contrib=false) initials='jp' initials='ag' initials='j' initials='a' initials='h' initials='am' initials='b' initials='n' initials='p' initials='k' author(firstnames='j' author(firstnames='g' author(firstnames='h' author(firstnames='a m' author(firstnames='p' author(firstnames='a' initials='d' affs=[]) initials='s' initials='m' initials='o' initials='f' initials='i' initials='r' initials='e' initials='v' author(firstnames='s' author(firstnames='n' author(firstnames='t' initials='t' author(firstnames='m' author(firstnames='d' author(firstnames='e' author(firstnames='k' author(firstnames='r' author(firstnames='v' initials='fj' initials='js' initials='ml' initials='z' equal_contrib=false)] lastname='mollee' lastname='prince' lastname='horvath' lastname='greil' lastname='van droogenbroeck' lastname='schots' author(firstnames='f' author(firstnames='z' author(firstnames='i' author(firstnames='o' pmid:22571200 doi:10.1056/nejmoa1112704 antonio palumbo roman hajek collabauthor(name='mm-015 investigators' investigators=[author(firstnames='b' lastname='augustson' lastname='joshua' lastname='spencer' lastname='taylor' author(firstnames='a g' lastname='gastl' lastname='ludwig' lastname='iskrov' lastname='uss' lastname='fillet' lastname='maisnar' lastname='scudla' lastname='gregersen' lastname='attal' author(firstnames='j p' lastname='fermand' lastname='jaccard' lastname='macro' author(firstnames='j -f' lastname='rossi' initials='j-' lastname='dölken' lastname='engelhardt' lastname='goldschmidt' lastname='knop' lastname='niederwieser' lastname='crotty' lastname='nagler' lastname='rowe' lastname='shpilberg' lastname='cafro' lastname='caravita' lastname='foa' lastname='gobbi' lastname='zweegman' lastname='dmoszynska' lastname='hellmann' author(firstnames='a b' lastname='skotnicki' initials='ab' lastname='abdulkadyrov' lastname='domnikova' lastname='osmanov' lastname='rossiev' lastname='rukavistin' lastname='alegre' author(firstnames='f j' lastname='capote' author(firstnames='m l' lastname='martino' author(firstnames='j s' lastname='miguel' lastname='ahlgren' lastname='bauer' lastname='stenner' lastname='cagirgan' lastname='schey' lastname='yong' lastname='kaplan' lastname='kyeting' lastname='lysa' lastname='maslyak' lastname='pylypenko' lastname='tretyak' lenalidomide melphalan / administration & dosage* melphalan / adverse effects multiple myeloma / drug therapy* multiple myeloma / mortality second primary / epidemiology thalidomide / administration & dosage thalidomide / adverse effects thalidomide / analogs & derivatives*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.